Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
This medication is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually.
The initial dose of this medication should be based on the patient's current treatment regimen.
1. Patients not currently receiving metformin:
For patients with no prior antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication.
2. Patients receiving metformin:
- For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medication is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose.
- Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin.
3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined by taking the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia.
Patients with renal impairment
This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment.
Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.
Improvement of glycemic control in patients with type 2 diabetes mellitus
View approved original textHide original text
This medication is used to help regulate blood sugar levels in patients with type 2 diabetes. Sitagliptin and Metformin work together to complement the effects of diet and exercise, helping to effectively manage blood sugar levels. In other words, this medication is used to stabilize blood sugar and improve diabetes management.
How to take
Adult dose
For antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
This medication is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually.
The initial dose of this medication should be based on the patient's current treatment regimen.
1. Patients not currently receiving metformin:
For patients with no prior antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication.
2. Patients receiving metformin:
- For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medication is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose.
- Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin.
3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined by taking the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia.
Patients with renal impairment
This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment.
Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.
Precautions
This medication consists of Sitagliptin and Metformin, and it helps to control blood sugar levels.
When taking this medication, severe allergic reactions may occur; therefore, if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a doctor.
Furthermore, acute pancreatitis, a serious inflammation of the pancreas, may occur, so if symptoms such as abdominal pain, vomiting, or loss of appetite arise, immediately notify medical personnel.
This medication should not be administered to patients with significantly impaired kidney function, severe infection, dehydration, or heart failure.
Especially when undergoing examinations using iodine contrast agents, this medication should be discontinued before and after the examination, and should only be resumed after confirming normal kidney function.
Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication.
During treatment, serious side effects such as hypoglycemia and lactic acidosis may occur, so caution is needed if meals are skipped or excessive exercise is performed.
Especially elderly patients or those with reduced kidney function should regularly monitor their kidney function, and if kidney function worsens, the medication should be discontinued immediately.
Alcohol consumption should be avoided during treatment, as alcohol can increase the risk of drug side effects.
Additionally, if taking other blood sugar-lowering medications or specific drugs, the risk of hypoglycemia may increase, so it is essential to inform your doctor or pharmacist about all medications being taken.
This medication may cause gastrointestinal disturbances, headaches, cold-like symptoms, etc., but they are generally mild.
If symptoms such as severe joint pain or skin blistering occur, consult medical personnel immediately.
In the event of surgery, this medication should be discontinued 48 hours prior to the surgery, and should only be resumed after confirming normal kidney function post-surgery.
Lastly, if excessive fatigue, muscle pain, difficulty breathing, or changes in consciousness occur during treatment, it is crucial to stop taking the medication and inform medical personnel immediately.
Finally, this medication has not been established as safe and effective for use in children under the age of 18.
Side effects
Anaphylaxis
angioedema
Stevens-Johnson syndrome
acute pancreatitis
lactic acidosis
hypoglycemia
diarrhea
upper respiratory infection
headache
nausea
Show 21 moreCollapse
vomiting
abdominal pain
nasopharyngitis
constipation
severe and disabling arthralgia
vesicular pemphigoid
myalgia
limb pain
back pain
interstitial lung disease
pruritus
thrombocytopenia
rhabdomyolysis
dyspnea
unstable angina
dizziness
acute renal failure
decreased appetite
itching
dermatitis
weight loss
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to prevent air exposure, and it is recommended to store it at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the efficacy and safety of the medication.
Appearance and packaging
Appearance
Pink oval film-coated tablet
Package unit
60 tablets/box [(10 tablets/PTP X 6)]
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.